Business Context and Reporting Period
This Form 8-K Current Report, dated September 10, 2025, pertains to MEI Pharma, Inc. (the "Company"), a Delaware corporation. The filing announces a corporate name change effective September 10, 2025, from MEI Pharma, Inc. to Lite Strategy, Inc.
Key Financial Metrics
This filing is a current report regarding a corporate governance change and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
- Corporate Name: Changed from MEI Pharma, Inc. to Lite Strategy, Inc.
- Stock Ticker Symbol: Effective September 11, 2025, the common stock will cease trading under the symbol "MEIP" and commence trading under the symbol "LITS" on the NASDAQ Capital Market.
- Shareholder Rights: The name change was effected via an amendment to the certificate of incorporation without a stockholder vote and does not alter stockholder rights.
Guidance, Outlook, and Risks
The filing includes a press release (Exhibit 99.1) announcing the name change. No financial guidance, operational outlook, or specific risk factors related to the name change are detailed in the text of this report. The filing notes that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the new ticker symbol "LITS" on the NASDAQ Capital Market starting September 11, 2025.
- Confirm the legal name change to Lite Strategy, Inc. in corporate registries.
- Review the attached Certificate of Amendment (Exhibit 3.1) for full legal details of the name change.
- Consult the press release (Exhibit 99.1) for any additional context regarding the strategic rationale for the rebranding.